ARIAD Pharmaceuticals Inc.

ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor.
Cancer Weekly; 11/17/2009; 1437 words; ...visit http://www.ariad.com. Gleevec[R...Bristol-Myers Squibb, Inc. Keywords: , Health...Trials, Oncology, Pharmaceutical, Technology, Acute...Leukemia, Antineoplastic, Ariad Pharmaceuticals Inc., Cancer, Chronic...

ARIAD Reports Third Quarter 2009 Development Progress and Financial Results.(Financial report)
Clinical Trials Week; 11/16/2009; 1084 words; ...Trials, Oncology, Pharmaceutical, Professional...Financial, Investing, Ariad Pharmaceuticals Inc., Bone, Clinical Trial Research, Pharmaceutical Business, Pharmaceutical...Therapy, Treatment, ARIAD Pharmaceuticals Inc. This article...

ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference.(Conference news)
Business Wire; 11/10/2009; 648 words; CAMBRIDGE, Mass. -- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced...and chief executive officer of ARIAD, is scheduled to provide an overview...collaboration with Merck & Co., Inc. ARIAD's second product candidate...

ARIAD to Present at the Oppenheimer 20th Annual Healthcare Conference.(Conference news)
Cancer Weekly; 11/10/2009; 874 words; ...Clinical Trials, Oncology, Pharmaceutical, Technology, Ariad Pharmaceuticals Inc., Cancer, Oncology, Pharmaceutical Business, Pharmaceutical Company, ARIAD Pharmaceuticals Inc. This article was prepared...

Ariad's AP24534 Featured in Cancer Cell Publication.
Health & Beauty Close-Up; 11/5/2009; 948 words; Ariad Pharmaceuticals, Inc. announced that the scientific journal...preclinical characterization of AP24534, Ariad's investigational, multi-targeted...is co-authored by scientists from Ariad, and collaborating investigators from...